Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine.

@article{Mustonen2000AtipamezoleAI,
  title={Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine.},
  author={P. Mustonen and J. Savola and R. Lassila},
  journal={Thrombosis research},
  year={2000},
  volume={99 3},
  pages={
          231-7
        }
}
To investigate the usefulness of atipamezole [MPV-1248, 4-(2-ethyl-2, 3-dihydro-1H-inden-2-yl)-1H-imidazole], a novel alpha(2)-adrenoceptor-specific antagonist, as a tool in platelet studies, the ability of this antagonist: (1) to bind to platelet alpha(2)-adrenoceptors, and (2) to inhibit adrenaline-induced platelet aggregation was compared to that of yohimbine, another commonly used alpha(2)-adrenoceptor antagonist. It was found that atipamezole binds to platelet alpha(2)-adrenoceptors more… Expand
Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanism.
Platelets in nonresponders to epinephrine stimulation showed reduced response to ADP.
...
1
2
...

References

SHOWING 1-10 OF 20 REFERENCES
Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole.
Nonadrenergic imidazoline binding sites on human platelets.
  • J. Piletz, K. Sletten
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental therapeutics
  • 1993
...
1
2
...